The Increasing Burden of HIV-Associated Malignancies in Resource-Limited Regions

被引:69
作者
Casper, Corey [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[3] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[4] Univ Washington, Dept Med, Seattle, WA 98195 USA
[5] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
来源
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 | 2011年 / 62卷
关键词
HIV; cancer; sub-Saharan Africa; Kaposi sarcoma; lymphoma; hepatocellular carcinoma; HUMAN-IMMUNODEFICIENCY-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HEPATITIS-B VACCINATION; KAPOSIS-SARCOMA; IMMUNE RECONSTITUTION; INFECTED PATIENTS; HEPATOCELLULAR-CARCINOMA; PROTEASE INHIBITOR; NEUTRALIZING ANTIBODIES;
D O I
10.1146/annurev-med-050409-103711
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cancer is increasingly recognized as a complication of MT infection in both resource-rich and resource-limited areas. The traditional AIDS-defining cancers, including Kaposi sarcoma, cervical cancer, and non-Hodgkin lymphoma, have become common comorbidities afflicting HIV-positive individuals and lack adequate prevention and management options. Additionally, several non-AIDS-defining cancers have increased in incidence in resource-limited regions, including Hodgkin lymphoma, hepatocellular carcinoma, and lung cancer. This review outlines the epidemiology of HIV-associated malignancies in resource-poor and resource-rich areas, including the impact of highly active antiretroviral therapy on the incidence of these cancers. The pathogenesis of HIV-associated cancers is considered in relation to potential strategies for their prevention and treatment.
引用
收藏
页码:157 / 170
页数:14
相关论文
共 71 条
[1]   Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: The impact of highly active antiretroviral therapy [J].
Aaron, L ;
Lidove, O ;
Yousry, C ;
Roudiere, L ;
Dupont, B ;
Viard, JP .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) :880-882
[2]  
[Anonymous], 2002, IARC Sci Publ, P1
[3]  
[Anonymous], 2008, WORLD CANC REPORT
[4]  
[Anonymous], 2009, FACT SHEETS
[5]  
[Anonymous], HLTH PEOPL AFR REG H
[6]  
[Anonymous], 2009, Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents
[7]  
Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823
[8]   Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen [J].
Bani-Sadr, F ;
Fournier, S ;
Molina, LM .
AIDS, 2003, 17 (10) :1580-1581
[9]   AIDS-Related cancer and severity of immunosuppression in persons with AIDS [J].
Biggar, Robert J. ;
Chaturvedi, Anil K. ;
Goedert, James J. ;
Engels, Eric A. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (12) :962-972
[10]   Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma [J].
Bihl, Florian ;
Mosam, Anisa ;
Henry, Leah N. ;
Chisholm, John V., III ;
Dollard, Sheila ;
Gumbi, Pamela ;
Cassol, Edana ;
Page, Taryn ;
Mueller, Nicolas ;
Kiepiela, Photini ;
Martin, Jeff N. ;
Coovadia, Hoosen A. ;
Scadden, David T. ;
Brander, Christian .
AIDS, 2007, 21 (10) :1245-1252